Advances in Prostate Cancer Biomarkers and Probes.

IF 10.5 Q1 ENGINEERING, BIOMEDICAL

Cyborg and bionic systems (Washington, D.C.) Pub Date : 2024-06-27 eCollection Date: 2024-01-01 DOI:10.34133/cbsystems.0129

Keyi Li, Qiao Wang, Xiaoying Tang, Ozioma Udochukwu Akakuru, Ruobing Li, Yan Wang, Renran Zhang, Zhenqi Jiang, Zhuo Yang

{"title":"Advances in Prostate Cancer Biomarkers and Probes.","authors":"Keyi Li, Qiao Wang, Xiaoying Tang, Ozioma Udochukwu Akakuru, Ruobing Li, Yan Wang, Renran Zhang, Zhenqi Jiang, Zhuo Yang","doi":"10.34133/cbsystems.0129","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.</p>","PeriodicalId":72764,"journal":{"name":"Cyborg and bionic systems (Washington, D.C.)","volume":"5 ","pages":"0129"},"PeriodicalIF":10.5000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063729/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cyborg and bionic systems (Washington, D.C.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34133/cbsystems.0129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.

查看原文本刊更多论文

前列腺癌生物标志物及探针研究进展

前列腺癌是全球男性最常见的恶性肿瘤之一，早期诊断对提高患者生存率至关重要。本文综述了前列腺癌生物标志物的最新进展，包括分子、细胞和外泌体生物标志物。强调各种生物标志物如基因融合物（TMPRSS2-ERG）、非编码rna （SNHG12）、蛋白质（PSA、PSMA、AR）和循环肿瘤细胞（ctc）在前列腺癌的诊断、预后和靶向治疗中的潜力。此外，本文还系统地探讨了多组学数据和人工智能技术如何用于生物标志物发现和个性化医疗应用。此外，本文综述了特异性探针的发展，包括荧光探针、电化学探针和放射性核素探针，以灵敏和准确地检测前列腺癌生物标志物。综上所述，本文对前列腺癌生物标志物的研究现状和未来发展方向进行了综述，并强调了其在精准诊断和靶向治疗方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊